The characteristics and clinical course of patients with melioidosis and cancer
PLOS Neglected Tropical Diseases · 25.10.2024 · 18 (10) · e0012631
DOI: 10.1371/journal.pntd.0012631 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 25.10.2024. Verfasst von Tej Shukla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cairns Hospital, Cairns, Queensland, Australia. Hauptthemen laut MEDLINE: Melioidosis, Neoplasms, Trimethoprim, Sulfamethoxazole Drug Combination. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with an active cancer are more likely to develop melioidosis, but the characteristics and clinical course of melioidosis in patients with cancer have not been examined in detail. Trimethoprim/sulfamethoxazole (TMP-SMX) prophylaxis is prescribed to prevent melioidosis in patients receiving immune suppressing anti-cancer therapy in some jurisdictions–and is recommended in national Australian guidelines–however the risks and benefits of this strategy are incompletely defined.
Methods
The study took place in Far North Queensland (FNQ) in tropical Australia. The characteristics and clinical course of patients with melioidosis diagnosed in the FNQ region between January 1, 1998, and June 1, 2023, who had–and did not have–an active cancer were compared. We also determined the subsequent incidence of melioidosis in patients receiving immune suppressing anti-cancer therapy in the FNQ region between January 1, 2008, and June 1, 2023, who did–and did not–receive TMP-SMX chemoprophylaxis for Pneumocystis jirovecii infection.
Results
An active cancer was present in 47/446 (11%) cases of melioidosis diagnosed between January 1, 1998, and June 1, 2023; there was no association between melioidosis and any cancer type. Patients with melioidosis and cancer were more likely to be older (odds ratio (OR) (95% confidence interval (CI): 1.05 (1.03–1.08) P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Cairns Hospital, Cairns, Queensland, Australia.
- Pharmacy department, Cairns Hospital, Cairns, Queensland, Australia.
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
ORCID-Profile: Josh Hanson
Zitieren
APA
Shukla, T., Smith, S., Johnstone, K., Donald, P., & Hanson, J. (2024). The characteristics and clinical course of patients with melioidosis and cancer. PLOS Neglected Tropical Diseases, 18(10), e0012631. https://doi.org/10.1371/journal.pntd.0012631
Vancouver
Shukla T, Smith S, Johnstone K, Donald P, Hanson J. The characteristics and clinical course of patients with melioidosis and cancer. PLOS Neglected Tropical Diseases. 2024;18(10):e0012631. doi:10.1371/journal.pntd.0012631
BibTeX
@article{Shukla2024,
author = {Shukla, Tej and Smith, Simon and Johnstone, Kristoffer and Donald, Patrick and Hanson, Josh},
title = {The characteristics and clinical course of patients with melioidosis and cancer},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
volume = {18},
number = {10},
pages = {e0012631},
doi = {10.1371/journal.pntd.0012631}
}
EUVIMED